Selling a Medical Billing / RCM Company in 2026: Multiples, Named Buyers, and the KPI Playbook

If you own a US medical billing or RCM company, the headline range (3x-11x EBITDA, with tech-enabled platforms commanding 12x-25x+) hides what actually sets your number: the operational KPIs. Two RCM companies at $2M of EBITDA can sell for $7M and $14M, and the difference is whether your Net Collection Rate is 92% or 96%, whether your DAR is 60 days or 38, whether your top-3 clients are 70% of revenue or 30%, and whether your workflows are manual or AI-augmented. RCM is one of the most aggressively consolidated healthcare sub-sectors in 2026 , R1 RCM at $8.9B, Waystar/Iodine at $1.25B, GeBBS at 17.2x EBITDA, EQT/KKR/Vista/Silver Lake all in market , and the bid for the right asset is the strongest it’s been in years. This guide gives you: the real multiples by company profile (with charts), the named buyer landscape and who backs each one, the KPI playbook buyers actually diligence, a preparation sequence in priority order, the dangers and traps that kill deals, and our view on where the market is going.

We are CT Acquisitions, a buy-side M&A advisory firm with buyers in our network actively acquiring medical billing and RCM companies. Sellers pay nothing, the buyer pays our fee at closing. For adjacent verticals, see our guides on selling a behavioral health practice, selling a home health agency, and healthcare business valuation.

What a medical billing / RCM company is actually worth in 2026

Revenue cycle management is one of the most aggressively acquired sub-sectors of healthcare services right now, and the multiples reflect it. The headline range for a US medical billing / RCM company in 2026 is roughly 3x to 11x EBITDA for typical lower-middle-market operators, with tech-enabled and AI-driven RCM platforms commanding 12x-25x+ EBITDA in strategic processes. The size of the spread is the whole story: a $500K-SDE owner-run billing shop and a $5M-EBITDA tech-enabled RCM platform are not the same asset class, and buyers price them entirely differently.

The multiples-by-size reality

(Multiples cited reflect typical 2026 transaction ranges and disclosed strategic deals; specific terms vary widely. A small specialty billing shop with stellar KPIs can beat the range; a mid-size company with high concentration can fall below it.)

Why the buyers care about RCM right now (the sector’s tailwind)

RCM is the operational backbone of every healthcare provider, and three things have made it one of the most actively consolidated healthcare-services sectors:

1. Structural demand. Healthcare providers under reimbursement pressure are outsourcing the RCM function rather than building it. The total US RCM outsourcing market is large and growing.
2. AI-driven margin expansion is real here. RCM is one of the few healthcare-services sub-sectors where AI/automation directly converts to margin (claim scrubbing, denial prediction, payer-rules automation, prior-auth automation). Buyers will pay tech multiples for the right platform.
3. Recurring, contracted revenue with very long tenure. Provider switching costs are enormous (data migration, payer enrollment refresh, training); a well-run RCM book has 90%+ revenue retention by default. Buyers love this profile.

The buyers acquiring RCM companies in 2026, by name

The operator-knowledge layer: the KPIs RCM buyers actually diligence

The headline number on an RCM company’s pitch deck (revenue, EBITDA, growth) tells you almost nothing about its real value. What RCM buyers diligence with surgical precision is whether the operational KPIs prove the business is durable. Get these right and you’ll move multiple turns; get them wrong and the deal gets repriced or dies.

Beyond the headline KPIs, buyers will diligence the layer of operational reality underneath:

• Client (provider) contract terms. Length, auto-renewal, termination provisions, change-of-control, exclusivity, pricing structure (percentage-of-collections vs PEPM vs flat fee), price escalators, payment terms.
• Specialty mix. Anesthesia, radiology, pathology, behavioral health, orthopedics, surgical specialties, primary care, ASCs, FQHCs , each has different reimbursement complexity, payer relationships, and benchmark margins. Specialty depth is a moat; jack-of-all-specialties without depth caps the multiple.
• Payer enrollment status. Which payers you’re credentialed/contracted with by client, the freshness of credentialing, any enrollment gaps that delay cash. Transferable enrollments matter on a sale.
• Compliance & HIPAA posture. BAAs in place with every client, documented security program, breach history (you want zero), recent OCR audit results, encryption of PHI at rest and in transit, access controls. A clean compliance file is table stakes; problems here are a hard discount or deal-killer.
• Technology stack and AI/automation depth. The PM/EHR systems you work in (Epic, athena, NextGen, eCW, etc.), your scrubbing engine, eligibility/prior-auth automation, denial prediction tools, RPA usage, any proprietary IP. Tech-enabled gets tech multiples; manual labor-heavy gets the bottom of the range.
• Staff structure. Onshore vs offshore (offshore can be a margin lever or a compliance flag depending on how it’s done), turnover, cross-training, supervisor depth. Loss of a key team is real risk.
• Quality of earnings defensibility. Owner-comp normalization, working-capital peg, percentage-of-collections revenue recognition done correctly, deferred revenue treatment, related-party items. A QoE re-cut can strip 10-25% of EBITDA from a sloppy presentation.

How to prepare a medical billing / RCM company for sale, in priority order

1. Get the KPI dashboard production-ready. Net Collection Rate, Days in A/R, A/R over 120 days, Denial Rate, Clean Claim Rate, First Pass Resolution, Cost to Collect , monthly, by client, by specialty, with 24-36 months of history. If you can’t produce this in a clean format, you’re not ready for diligence. This is the #1 thing buyers will ask for in the first call.
2. Push the KPIs themselves toward best-in-class. NCR to 96%+, DAR below 45, denials under 6%, clean claim rate above 90%. Every move toward best-in-class is justifiable multiple expansion. A 12-month KPI improvement project before going to market routinely adds turns to the multiple.
3. De-risk client concentration. Top-3 client share, top-5, top-10. A heavily concentrated book gets discounted or restructured into an earn-out tied to retention. Where you have the leverage, lock big clients into multi-year auto-renewing contracts with reasonable termination provisions before listing.
4. Invest in tech/automation , and document it. Even if you can’t get to “tech platform” multiples, demonstrable AI-augmented workflows (denial prediction, automated eligibility, RPA on routine tasks) move you up the range and signal a different operating model. Document what you’ve built, what it cost, and what KPI lift it produced.
5. Clean the compliance and HIPAA file. Every client BAA current and on file, security program documented (SOC 2 if you can swing it), zero open OCR matters, breach response plan tested, access controls audited. This is gating; problems here can kill a deal in a week.
6. Specialty depth and credentialing. Pick your 2-3 strongest specialties and document the depth (coders certified, payer relationships, claim volume, specialty-specific KPIs); refresh credentialing across the book; identify enrollment gaps and close them.
7. QoE-ready financials. Accrual accounting, documented owner-comp normalization, correct revenue recognition (percentage-of-collections vs cash, deferred revenue), working-capital peg analysis, 2-3 years cleaned with a defensible add-back schedule. Hire a sell-side QoE for a $3M+ EBITDA business , it pays for itself many times over by holding the multiple in diligence.
8. Document the operating model. SOPs by function (intake, eligibility, coding, scrubbing, submission, posting, denials, AR follow-up, patient billing), the org chart, supervisor depth. The buyer’s biggest fear is “does this run without the founder?” , give them the answer in writing.

The dangers and traps: what kills RCM company deals in diligence

• KPIs that fall apart under buyer scrutiny. NCR you report at 96% but the buyer recalculates at 89% because you’ve been writing off bad receivables aggressively. This is the most common RCM deal-killer. Buyers will reconstruct your KPIs from raw claim-level data , if your reported numbers don’t survive that test, the multiple craters.
• Hidden bad debt in the 120+ A/R bucket. An old A/R tail you’ve never reserved against properly. The buyer adjusts the working-capital peg or strikes the deal value.
• Concentration in a single client / specialty / payer. Top client 25%+ of revenue, single specialty 60%+ of book, single payer dependency. Each is a structural risk the buyer prices in.
• HIPAA / OCR exposure. An open OCR complaint, a recent breach you handled informally, missing BAAs, an offshore vendor with inadequate safeguards. Gating.
• Owner-dependency. The founder personally holds the client relationships, owns the coding decisions, runs the operations. Buyer is buying a job, not a business.
• Tech debt. Multiple disjointed systems, manual processes that should be automated, no real automation roadmap. Caps the multiple at the bottom of the range and creates a real integration cost for the buyer.
• Payer enrollment gaps. Credentialing that lapsed, clients added without proper enrollment, payer/credentialing changes that delayed cash. The buyer treats this as a working-capital adjustment.
• Bad EBITDA hygiene. Owner comp not normalized, related-party expenses, percentage-of-collections revenue recognition done on cash basis when it should be accrual, deferred revenue not properly reflected. A QoE re-cut strips the difference, and your EBITDA multiple is now applied to a smaller number.
• Staff flight risk in offshore operations. If you’ve built a large offshore team and they’re not contractually locked in or properly supervised, the buyer prices in the cost of rebuilding it.

Our view on where the RCM M&A market is going

The RCM space is in a multi-year consolidation wave with no signs of slowing. Three forces are converging: the take-private of R1 RCM at $8.9B confirms public-market RCM was undervalued and unlocks aggressive add-on activity under PE ownership; EQT’s bet on GeBBS at 17.2x EBITDA and Vista’s on Model N at ~25x show what tech-enabled RCM commands; and the entire wave of PE-backed roll-up platforms (Ensemble, CorroHealth, the New Mountain payment-integrity platform, plus the dedicated healthcare-services sponsors) is on a sustained add-on cadence , June 2025 alone had at least four RCM PE deals, all add-ons.

The implication for an owner: the bid for the right RCM company is the strongest it has been in years, and the gap between average and best-in-class is widening. A $2M-EBITDA single-specialty billing company on manual workflows with messy KPIs and one big client trades at 3.5x , the bottom of the range. The same $2M-EBITDA company with 96%+ NCR, sub-45 DAR, AI-augmented workflows, 4+ stable mid-size clients, and a SOC 2 trades at 6-7x, and a strategic that needs your specialty can pay above that. That’s a 2-3x EBITDA difference, $4-6M of enterprise value swing on the same business, controllable over a 12-24 month preparation window. The window is open and probably stays open through 2026-2027; the premium is for the prepared asset.

Related guides: healthcare business valuation, selling a behavioral health practice, selling a home health agency, selling an ABA therapy business, selling a medical device manufacturer, selling an IT / MSP business, selling a cybersecurity services company, how private equity creates value, which industries PE is buying most, sell your business, the buyer-paid broker alternative, business brokers by state, how to value a small business, about CT Acquisitions, or use our free valuation tool or book a confidential call.

The five pillars of how CT Acquisitions works

Frequently asked questions

How much is my medical billing / RCM company worth in 2026?

US medical billing / RCM companies typically sell for roughly 3x to 11x EBITDA, with tech-enabled and AI-driven RCM platforms commanding 12x to 25x+ EBITDA in strategic processes. By size: small owner-operated billing companies (under $1M adjusted EBITDA) typically transact at 2.5x-4x EBITDA; mid-size companies ($1M-$3M EBITDA) at 3.5x-6x; larger platforms ($3M+ EBITDA, $5-50M revenue) at 6x-11x; tech/AI-driven RCM platforms at 12x-25x+ (GeBBS Healthcare sold to EQT at $850M / 17.2x EBITDA; Model N sold to Vista at ~25x EBITDA; R1 RCM went private at $8.9B). The biggest drivers within the range are operational KPIs (net collection rate, days in A/R, denial rate, clean claim rate), client and specialty concentration, the technology stack, and HIPAA/compliance hygiene. Use our free valuation tool for a sector-adjusted estimate.

Which KPIs do RCM buyers diligence most carefully?

The headline ones, in order: Net Collection Rate (>95-96% per the MGMA benchmark; world-class is 98%+), Days in Accounts Receivable (<40-50 days; best-in-class <35), A/R over 120 days as % of total A/R (<15%; world-class <10%), Denial Rate (<5-7%), Clean Claim Rate / first-pass acceptance (>90%; world-class >95%), First Pass Resolution Rate (>85%), and Cost to Collect (4-6% for medical groups, lower for tech-enabled). Buyers will reconstruct these from raw claim-level data, not just trust your reports, and if your numbers don’t survive the rebuild the multiple craters. They also diligence payer mix breakdown, client contract terms (length, termination, change-of-control, pricing structure), specialty mix and depth, payer enrollment/credentialing status, HIPAA compliance file (BAAs, SOC 2 if you have it, breach history), technology stack and automation depth, staff structure (onshore vs offshore, turnover), and quality-of-earnings defensibility.

Who is buying medical billing / RCM companies in 2026?

The buyer pool is unusually deep. R1 RCM was taken private by TowerBrook Capital + Clayton, Dubilier & Rice in an $8.9B deal. Waystar (public) acquired Iodine Software for $1.25B in October 2025; Waystar itself was previously a $2.7B EQT/CPPIB take-private before its IPO. Ensemble Health Partners is backed by Berkshire Partners and Warburg Pincus. CorroHealth (Carlyle, Patient Square Capital) acquired Xtend Healthcare from Navient for $365M. EQT acquired GeBBS Healthcare Solutions for $850M (4.3x revenue / 17.2x EBITDA). New Mountain Capital merged The Rawlings Group + Apixio Payment Integrity + VARIS into a payment-integrity platform. Vista, KKR, Silver Lake, and Carlyle are the most active dedicated PE buyers; the existing platforms (above) are doing constant add-ons; June 2025 alone had at least 4 RCM PE deals, all add-ons. Strategic acquirers (large healthcare-IT companies, MSO/PPM platforms, payer-services rollups) compete with PE for specialty depth. Search funders buy smaller, owner-operated specialty billing companies. CT also has buyers in its network that specifically target healthcare RCM.

Why do tech-enabled / AI-driven RCM companies trade at 20x+ EBITDA?

Because the market treats genuinely tech-enabled RCM as healthcare-IT, not healthcare-services. The reasoning: AI/automation in RCM (denial prediction, eligibility automation, prior-auth automation, claim scrubbing, RPA on routine tasks, payer-rules engines) directly converts to margin expansion at the platform level, which is a recurring, software-like dynamic rather than a labor-arbitrage one. Tech-enabled platforms also scale more cleanly (margin doesn’t degrade with growth the way it does in labor-heavy operations), have stickier client relationships (clients integrated into the platform have high switching costs), and attract a different buyer pool that includes healthcare-IT strategics and tech-focused PE (Vista, Silver Lake, KKR’s tech franchise). The bar is real, though: ‘we use some software’ isn’t tech-enabled; proprietary IP, demonstrable AI workflows, scalable SaaS revenue, and enterprise hospital clients are what command the premium. GeBBS to EQT at 17.2x and Model N to Vista at ~25x are representative.

How does client concentration affect my RCM company’s valuation?

Significantly. A heavily concentrated book , say top-3 clients at 50%+ of revenue , gets either a 10-25% multiple discount or restructured into an earn-out tied to client retention, because the buyer is underwriting a few relationships that could each terminate after closing. The diligence answer to concentration isn’t ‘they’ve been with us 10 years’ , it’s documented multi-year auto-renewing contracts with reasonable termination provisions, low historical churn data, and ideally specialty depth that creates real switching costs (you handle their anesthesia billing across 8 facilities; nobody can replicate that in 90 days). If you’re contemplating a sale and have concentration, the prep work is winning new logos and growing smaller clients to bring the top-3 share down, plus locking in the big clients on terms that survive diligence. This is a 12-24 month project that routinely shifts the multiple by 1-2 turns.

What KPI improvements should I focus on before selling my RCM company?

In priority order: (1) Net Collection Rate , move from 92-93% to 96%+. This is the single most important KPI and direct multiple-mover. Tighten denial management, AR follow-up workflow, write-off discipline. (2) Days in A/R , push toward <45. Front-end (eligibility, prior auth) improvements + back-end (denial work queues) is the path. (3) A/R over 120 days , reduce to <15% of total A/R. Either work the aging tail or properly reserve and write off; either way buyers want to see it clean. (4) Denial Rate , get under 6%. Better front-end edits, eligibility automation, coding QA. (5) Clean Claim Rate , above 90%. Often a clearinghouse + scrubber + workflow issue. (6) Cost to Collect , work toward 5% or below via automation. Each of these is independently justifiable as multiple expansion, and the combination over 12-18 months can move you from a 3.5x business to a 6x business on the same EBITDA , a literal doubling of enterprise value. Document the baseline, document the improvement, present the trend in your CIM.

How long does it take to sell a medical billing / RCM company?

Traditional broker-listed RCM companies typically take 9-15 months. Off-market sales to a PE-backed RCM platform, a larger strategic RCM company, or a dedicated healthcare-services sponsor typically take 90-180 days, because the buyer is pre-qualified, actively rolling up, and looking specifically for companies in your size range, specialty mix, and KPI profile. RCM diligence is well-trodden ground for these acquirers , they reconstruct your KPIs from raw data, verify the contract book, audit the HIPAA file, do payer-enrollment review, and run a tight QoE , and that work goes fast because they’ve done it many times. Many RCM deals with concentrated client books include an earn-out tied to client retention that extends the full payout timeline 12-24 months beyond closing; well-prepared, low-concentration sales pay out cleanly at close.

Do I need a business broker to sell my medical billing / RCM company?

For a small specialty billing shop (under $1M EBITDA), a healthcare-focused business broker can work but charges 8-15% commissions. For mid-size and platform-scale RCM companies, a buyer-paid sell-side advisor with direct relationships into the major RCM platforms (R1 RCM, Waystar, Ensemble, CorroHealth, GeBBS, the New Mountain platform), the dedicated healthcare-services PE sponsors (Vista, KKR, Silver Lake, Carlyle, Berkshire, Warburg, Patient Square), and strategic acquirers usually produces better outcomes , higher multiples (often 1-2 turns above what a broker pulls from a generic marketing process), better-matched buyers, faster close, and no seller fee (the buyer pays at closing). A properly run competitive process that puts more than one platform in play almost always lifts the price in this sector, especially given how many active acquirers there are right now.

Related research

• Free Business Valuation Tool, your business is worth in 90 seconds
• The Business Broker Alternative Guide (national pillar)
• Business Brokers by State, with a free alternative
• The Complete Guide to Selling Your Business in 2026
• What’s My Business Worth? Founder’s Valuation Guide
• Who Buys These Companies? Buyer Types Explained
• How to Sell to Private Equity, A Founder’s Walkthrough
• Owner’s Pre-Exit Checklist, 90 Days Before You List
• CT Commentary, Founder & M&A Insights

About the Author

Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch